tq-b3139
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2017 (NCT03099330)
Timeline
Indications
Mechanism of action
ACVRL1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tq-b3139
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04675060 | Phase 1 | Dec 31, 2020 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04398940 | Phase 2 | Jun 1, 2020 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04056572 | Phase 2 | Sep 1, 2019 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04009317 | Phase 3 | Aug 1, 2019 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Sun Yat-Sen University |
| NCT03099330 | Phase 1 | Mar 1, 2017 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 5 | 5 | 3 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1